drugset / Trial / NCT00312026

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

NCT00312026

Phase 4 Completed 75 enrolled Genentech, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase IV randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SC efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque psoriasis involving the hands and/or feet who have had no previous exposure to efalizumab. The study will consist of a screening period, a treatment period, and an observation period.

Timeline

Start
2006-03-30
Primary completion
2006-11-28
Completion
2006-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject efalizumab Monoclonal antibody 1 mg/kg Subcutaneous

Indications